• Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1 

      Bastard, Paul; Orlova, Elizaveta; Sozaeva, Leila S.; Lévy, Romain; James, Alyssa; Schmitt, Monica M; Ochoa, Sebastian; Kareva, Maria; Rodina, Yulia; Gervais, Adrian; Le Voyer, Tom; Rosain, Jérémie; Philippot, Quentin; Neehus, Anna-Lena; Shaw, Elana; Migaud, Mélanie; Bizien, Lucy; Ekwall, Olov; Berg, Stefan; Beccuti, Guglielmo; Ghizzoni, Lucia; Thiriez, Gerard; Pavot, Arthur; Goujard, Cecile; Fremond, Marie-Louise; Carter, Edwin; Rothenbuhler, Anya; Linglart, Agnès; Mignot, Brigite; Comte, Aurelie; Cheikh, Nathalie; Hermine, Olivier; Breivik, Lars Ertesvåg; Husebye, Eystein Sverre; Humbert, Sebastien; Rohrlich, Pierre; Coaquette, Alain; Vuoto, Fanny; Faure, Karine; Mahlaoui, Nizar; Kotnik, Primoz; Battelino, Tadej; Podkrajšek, Katarina Trebušak; Kisand, Kai; Ferre, Elise M.N.; DiMaggio, Thomas; Rosen, Lindsey B.; Burbelo, Peter D.; McIntyre, Martin; Casanova, Jean-Laurent; Lionakis, Michail (Journal article; Peer reviewed, 2021)
      Patients with biallelic loss-of-function variants of AIRE suffer from autoimmune polyendocrine syndrome type-1 (APS-1) and produce a broad range of autoantibodies (auto-Abs), including circulating auto-Abs neutralizing ...